Topiramate weight loss in migraine patients.
Topiramate (TPM) is generally recognized efficacious and safe in migraine prevention. A significant proportion of patients undergoing TPM administration may show weight loss. In epileptic subjects, high body mass index (BMI) was found to be predictive of weight loss under TPM therapy. We therefore aimed to study whether common clinical determinants may be associated to TPM weigh loss in migraine patients. In our clinical series, high BMI was not found a predictor of weight loss under TPM treatment. Unknown genetic and environmental factors that may determine the courses of weight loss under TPM therapy are still do be identified.
Alberici
Antonella
A
Neurology Unit, Department of Medical and Surgical Sciences, University of Brescia, Italy. antoalberici@yahoo.it
Borroni
Barbara
B
Manelli
Filippo
F
Griffini
Simona
S
Zavarise
Paola
P
Padovani
Alessandro
A
Dalla Volta
Giorgio
G
D000328:Adult; D015992:Body Mass Index; D005260:Female; D005632:Fructose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D016014:Linear Models; D008297:Male; D008881:Migraine Disorders / Q000188:drug therapy* / Q000503:physiopathology; D011446:Prospective Studies; D000077236:Topiramate; D015431:Weight Loss / Q000187:drug effects*
D000077236:Topiramate; D005632:Fructose